Redwood City, California -- Genomic diagnostics company CardioDx has secured $7.4 million in its fourth round of venture capital financing, according to an SEC regulatory filing.
CardioDx provides "clinically validated genomic tests to aid in assessing in tailoring care of individuals with cardiovascular disease."
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 15 investors have participated in the offering to date.
CardioDx is still seeking $13 million in additional equity investment, according to the filing.